MLL leukemia induction by genome editing of human CD34+ hematopoietic cells
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Key Points: Genome editing of primary human HSPCs generates MLL leukemias that model clinical disease features and molecular pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these events occur at low frequency, they could be significant in a clinical setting if rare translocations led to cancer 97-99 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [97]
Citations
Cites
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · cited 2×
“The rapid progression of gene edited HSPCs to a fully developed leukemia phenotype in vivo supports the hypothesis, based on clinical and genomic observations, that MLL fusion genes require fewer cooperating oncogenic events for leukemic transformation than other fusion oncoproteins.(5,7) This is consistent with MLL r…”
BackgroundThe DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390 · cited 3×
“Additionally, we quantified allele modification frequencies using TIDE analysis (Figure 1D).(21) The MLL TALEN pair most efficient at cleavage was used in subsequent experiments to target a DNA DSB at the preselected genomic site of the MLL gene in primary cells.”
MethodInfluentialCermak, T., Doyle, E. L., Christian, M., Wang, L., Zhang, Y., Schmidt, C., Baller, J. A., Somia, N. V., Bogdanove, A. J., & Voytas, D. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr218 · Cited by 1,787 · cited 3×
“Three pairs of TALENs were created using the Golden Gate TALEN Assembly Method.(19) Following nucleofection of the TALEN pairs, genomic DNA was isolated and the targeted region of interest was amplified by PCR with MLL-specific primers (5’GCCTTTTAATAGTCCGTGTCT3’ and 5’TCTTTAGCTGGTTTAAACAGG3’) and analyzed using the T7…”
BackgroundMethodInfluentialTALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650
A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum
Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J., Baird, M. A., Sell, B. R., Allen, J. R., Day, R. N., Israelsson, M., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2413 · Cited by 1,289 · cited 2×
“The knock-in DNA templates contained MLL homology arms (;700 bp) flanking the TALENcleavage site, fusion partner complementaryDNA (cDNA) sequences, an internal ribosomal entry site (IRES), a fluorescent marker gene coding NeonGreen, and a polyA tail (nucleotide sequences provided in supplemental Figure 1, see suppleme…”
MethodSelective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923 · cited 1×
“Small-molecule inhibitors of DOT1L have been developed and are currently undergoing phase I clinical trials.(45-50) We tested leukemic blast cells explanted from MPAL and AML mice for sensitivity to the DOT1L inhibitor EPZ004777 in comparison with the human MLL-rearranged leukemia cell line MV4-11 and non-MLL rearrang…”
MethodhDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 804 · cited 1×
“DOT1L catalyzes the methylation of H3K79, a chromatin modification that leads to enhanced expression of leukemogenic genes, including HOXA9 and MEIS1 in MLLrearranged leukemias.(34-44) Small-molecule inhibitors of DOT1L have been developed and are currently undergoing phase I clinical trials.”
Background
Cited by
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
VRACs and other ion channels and transporters in the regulation of cell volume and beyond
Jentsch, T. J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.29 · Cited by 353
Mouse models of MLL leukemia: recapitulating the human disease
Milne, T. A. (2017) · Blood · doi:10.1182/blood-2016-10-691428 · Cited by 108
Tóthová, Z., Krill-Burger, J. M., Popova, K. D., Landers, C. C., Sievers, Q. L., Yudovich, D., Belizaire, R., Aster, J. C., Morgan, E. A., Tsherniak, A., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.015 · Cited by 110
“nucleases (TALENs), and RNA-guided nucleases (CRISPR/ Cas9), have been successfully employed to edit human HSPC (Buechele et al., 2015; Dever et al., 2016; Genovese et al., 2014b; Gundry et al., 2016; Mandal et al., 2014).”
BackgroundMethodChan, A., & Chen, C.-W. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00081 · Cited by 95
Metadata
- Authors
- Buechele, C., Breese, E. H., Schneidawind, D., Lin, C.-H., Jeong, J., Duque-Afonso, J., Wong, S. H. K., Smith, K. S., Negrin, R. S., Porteus, M., & Cleary, M. L.
- Affiliations
- Department of Pathology,
- Division of Pediatric Hematology/Oncology, Department of Pediatrics,
- Division of Blood and Marrow Transplantation, Department of Medicine, and
- Stanford Medicine (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-10-01
- Volume
- 126
- Issue
- 14
- Pages
- 1683-1694
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4591792
- OpenAlex
- W2165896516
- Cited by
- 60
- References
- 63
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 6 · 2018: 7 · 2017: 7 · 2016: 12 · 2015: 2
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Hematology Association (TRTH105)
- National Cancer Institute (CA 116606, R01CA160384, CA160384, R01CA116606)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- MLL leukemia, MLL-AF9, MLL-ENL, TALEN, genome editing, hematopoietic stem and progenitor cells, CD34+ cells, umbilical cord blood, acute leukemia, leukemia induction, DOT1L inhibition, MLL, leukemia stem cells, disease modeling
- MeSH terms
- Animals, Cell Separation, Cell Transformation, Neoplastic, Disease Models, Animal, Hematopoietic Stem Cells, Humans, Histone-Lysine N-Methyltransferase, Transduction, Genetic, Transfection, Leukemia, Biphenotypic, Acute, Genome, Human, Polymerase Chain Reaction, Mutagenesis, Site-Directed, Microscopy, Confocal, Antigens, CD34, Oligonucleotide Array Sequence Analysis, Mice, Myeloid-Lymphoid Leukemia Protein, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MLL leukemia induction by genome editing of human CD34+ hematopoietic cells. https://app.cochat.ai/papers/10.1182/blood-2015-05-646398
- The paper
- Buechele, C., Breese, E. H., Schneidawind, D., Lin, C.-H., Jeong, J., Duque-Afonso, J., Wong, S. H. K., Smith, K. S., Negrin, R. S., Porteus, M., & Cleary, M. L. (2015). MLL leukemia induction by genome editing of human CD34+ hematopoietic cells. Blood. https://doi.org/10.1182/blood-2015-05-646398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.